Ionis Pharmaceuticals (IONS) EBIAT (2016 - 2025)
Ionis Pharmaceuticals (IONS) has 17 years of EBIAT data on record, last reported at -$229.4 million in Q4 2025.
- For Q4 2025, EBIAT fell 119.83% year-over-year to -$229.4 million; the TTM value through Dec 2025 reached -$381.4 million, up 15.98%, while the annual FY2025 figure was -$381.4 million, 15.97% up from the prior year.
- EBIAT reached -$229.4 million in Q4 2025 per IONS's latest filing, down from -$128.6 million in the prior quarter.
- Across five years, EBIAT topped out at $224.6 million in Q4 2021 and bottomed at -$229.4 million in Q4 2025.
- Average EBIAT over 5 years is -$75.0 million, with a median of -$87.6 million recorded in 2021.
- Peak YoY movement for EBIAT: tumbled 1026.51% in 2024, then skyrocketed 286.45% in 2025.
- A 5-year view of EBIAT shows it stood at $224.6 million in 2021, then tumbled by 123.34% to -$52.4 million in 2022, then skyrocketed by 82.33% to -$9.3 million in 2023, then crashed by 1026.51% to -$104.3 million in 2024, then tumbled by 119.83% to -$229.4 million in 2025.
- Per Business Quant database, its latest 3 readings for EBIAT were -$229.4 million in Q4 2025, -$128.6 million in Q3 2025, and $123.6 million in Q2 2025.